Antiinflammatory action of glucocorticoids - New mechanisms for old drugs

New England Journal of Medicine

Volumn 353, Issue 16, 2005, Pages

  Rhen, Turk ^a   Cidlowski, John A ^b,c  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INSULIN; INSULIN DERIVATIVE; MIFEPRISTONE; UNCLASSIFIED DRUG;

ACNE; ADRENAL CORTEX ATROPHY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATROPHY; BEHAVIOR DISORDER; BONE DISEASE; BONE NECROSIS; BRAIN ATROPHY; CATARACT; COGNITIVE DEFECT; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DELAYED PUBERTY; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; ERYTHEMA; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; INFLAMMATORY DISEASE; INTEGUMENT; INTRAUTERINE GROWTH RETARDATION; MEDICAL PRACTICE; MEMORY DISORDER; METABOLIC DISORDER; MOOD DISORDER; MUSCLE ATROPHY; NEUROENDOCRINE SYSTEM; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PERIORAL DERMATITIS; PETECHIA; PLEIOTROPY; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SODIUM RETENTION; STEROID THERAPY; STRIA; TELANGIECTASIA; THROMBOSIS; VASCULITIS; VIRUS REACTIVATION; WOUND HEALING IMPAIRMENT;

ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; RECEPTORS, GLUCOCORTICOID;

EID: 26844433194     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra050541     Document Type: Review

References (92)

1. Gallin JI, Goldstein IM, Snyderman R. Overview. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. 2nd ed. New York: Raven Press, 1992:1-4.
2. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002;20:125-63.
3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43.
4. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2:119-25.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
6. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003;112:460-7.
7. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
8. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2001;26:761-88.
9. Breuner CW, Orchinik M. Plasma binding proteins as mediators of corticosteroid action in vertebrates. J Endocrinol 2002;175:99-112.
10. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004;2:1-12.
11. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J 1992;11:1003-13.
12. Rhen T, Cidlowski JA. Steroid hormone action. In: Strauss JF III, Barbieri RL, eds. Yen and Jaffe's reproductive endocrinology. 5th ed. Philadelphia: Elsevier Saunders, 2004:155-74.
13. Hebbar PB, Archer TK. Chromatin remodeling by nuclear receptors. Chromosoma 2003;111:495-504.
14. Nagaich AK, Rayasam GV, Martinez ED, et al. Subnuclear trafficking and gene targeting by steroid receptors. Ann N Y Acad Sci 2004;1024:213-20.
15. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-59.
16. De Bosscher K, Vanden Berghe W, Haegeman G. Interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522.
17. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-9.
18. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002;2002(138):RE9.
19. Lu NZ, Cidlowski JA. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci 2004;1024:102-23.
20. Zhang T, Haws P, Wu Q. Multiple variable first exons: a mechanism for cell- and tissue-specific gene regulation. Genome Res 2004;14:79-89.
21. Pedersen KB, Vedeckis WV. Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry 2003;42:10978-90.
22. Pujols L, Mullol J, Perez M, et al. Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol 2001;24:49-57.
23. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A 2001;98:6865-70.
24. Gagliardo R, Vignola AM, Mathieu M. Is there a role for glucocorticoid receptor beta in asthma? Respir Res 2001;2:1-4.
25. Torrego A, Pujols L, Roca-Ferrer J, Mullol J, Xaubet A, Picado C. Glucocorticoid receptor isoforms alpha and beta in in vitro cytokine-induced glucocorticoid insensitivity. Am J Respir Crit Care Med 2004;170:420-5.
26. Yudt MR, Cidlowski JA. Molecular identification and characterization of A and B forms of the glucocorticoid receptor. Mol Endocrinol 2001;15:1093-103.
27. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005;18:331-42.
28. Ismaili N, Garabedian MJ. Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci 2004;1024:86-101.
29. Wallace AD, Cidlowski JA. Proteasomemediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;276:42714-21.
30. Wang X, Pongrac JL, DeFranco DB. Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-dependent down-regulation but maintain transactivation activity. Mol Endocrinol 2002;16:1987-98.
31. Le Drean Y, Mincheneau N, Le Goff P, Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002;143:3482-9.
32. Holmstrom S, Van Antwerp ME, Iniguez-Lluhi JA. Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy. Proc Natl Acad Sci U S A 2003;100:15758-63.
33. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-38.
34. Delbende C, Delarue C, Lefebvre H, et al. Glucocorticoids, transmitters, and stress. Br J Psychiatry 1992;Suppl 15:24-35.
35. Miller DB, O'Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism 2002;51:Suppl 1:5-10.
36. Kapcala LP, Chautard T, Eskay RL. The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Ann N Y Acad Sci 1995;771:419-37.
37. Meduri GU, Yates CR. Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci 2004;1024:24-53.
38. Chikanza IC. Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann N Y Acad Sci 2002;966:39-48.
39. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004;113:619-27.
40. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004;114:1059-69.
41. Solito E, de Coupade C, Parente L, Flower RJ, Russo-Marie F. IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein. Cytokine 1998;10:514-21.
42. Mizuno H, Uemura K, Moriyama A, et al. Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Brain Res 1997;746:256-64.
43. Antonicelli F, De Coupade C, Russo-Marie F, Le Garrec Y. CREB is involved in mouse annexin A1 regulation by cAMP and glucocorticoids. Eur J Biochem 2001;268:62-9.
44. Kim SW, Rhee HJ, Ko J, et al. Inhibition of cytosolic phospholipase A2 by annexin I: specific interaction model and mapping of the interaction site. J Biol Chem 2001;276:15712-9.
45. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull 2004;27:1168-73.
46. Roviezzo F, Getting SJ, Paul-Clark MJ, et al. The annexin-1 knockout mouse: what it tells us about the inflammatory response. J Physiol Pharmacol 2002;53:541-53.
47. Lim LH, Solito E, Russo-Marie F, Flower RJ, Perretti M. Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Proc Natl Acad Sci U S A 1998;95:14535-9.
48. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci 2002;966:108-18.
49. Mulla A, Leroux C, Solito E, Buckingham JC. Correlation between the antiinflammatory protein annexin 1 (lipocortin 1) and serum cortisol in subjects with normal and dysregulated adrenal function. J Clin Endocrinol Metab 2005;90:557-62.
50. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
51. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22:7802-11.
52. Toh ML, Yang Y, Leech M, Santos L, Morand EF. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum 2004;50:3118-28.
53. Rhen T, Cidlowski JA. Nuclear factor-κB and glucocorticoid receptors. In: Martini L, ed. Encyclopedia of endocrine diseases. Vol. 3. Boston: Elsevier Academic Press, 2004:391-8.
54. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114.
55. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2314-29.
56. Bladh LG, Liden J, Dahlman-Wright K, Reimers M, Nilsson S, Okret S. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol Pharmacol 2005;67:815-26.
57. Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998;12:221-34.
58. Ortiz PA, Garvin JL. Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol 2003;284:R628-R638.
59. Perretti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation 2000;7:147-61.
60. Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory response genes. Biochem Soc Symp 2003;70:95-106.
61. Gille J, Reisinger K, Westphal-Varghese B, Kaufmann R. Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. J Invest Dermatol 2001;117:1581-7.
62. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
63. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 1999;41:55-64.
64. Brieva J, Wanner A. Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects. J Appl Physiol 2001;90:665-9.
65. Brieva JL, Danta I, Wanner A. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med 2000;161:293-6.
66. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002;15:35-50.
67. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112:Suppl 3:S1-S40.
68. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.
69. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003;24:782-801.
70. Chrysis D, Zaman F, Chagin AS, Takigawa M, Savendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 2005;146:1391-7.
71. Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 2004;10:2807-16.
72. Iwamoto J, Takeda T, Sato Y. Effects of vitamin K2 on osteoporosis. Curr Pharm Des 2004;10:2557-76.
73. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81.
74. Sato S, Kim T, Arai T, Maruyama S, Tajima M, Utsumi N. Comparison between the effects of dexamethasone and indomethacin on bone wound healing. Jpn J Pharmacol 1986;42:71-8.
75. Seidenberg AB, An YH. Is there an inhibitory effect of COX-2 inhibitors on bone healing? Pharmacol Res 2004;50:151-6.
76. Beer HD, Fassler R, Werner S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000;59:217-39.
77. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-85.
78. Richardson DW, Dodge GR. Dosedependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes. Inflamm Res 2003;52:39-49.
79. Cutroneo KR. How is Type I procollagen synthesis regulated at the gene level during tissue fibrosis. J Cell Biochem 2003;90:1-5.
80. Nuutinen P, Riekki R, Parikka M, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol 2003;148:39-45.
81. Dallman MF, Strack AM, Akana SF, et al. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 1993;14:303-47.
82. Mitch WE. Mechanisms accelerating muscle atrophy in catabolic diseases. Trans Am Clin Climatol Assoc 2000;111:258-69.
83. Leal-Cerro A, Soto A, Martinez MA, Dieguez C, Casanueva FF. Influence of cortisol status on leptin secretion. Pituitary 2001;4:111-6.
84. Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care 2003;30:593-605.
85. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004;101:227-32.
86. Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002;110:93-105.
87. Kauppi B, Jakob C, Farnegardh M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003;278:22748-54.
88. Garside H, Stevens A, Farrow S, et al. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004;279:50050-9.
89. Coghlan MJ, Elmore SW, Kym PR, Kort ME. The pursuit of differentiated ligands for the glucocorticoid receptor. Curr Top Med Chem 2003;3:1617-35.
90. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and nongenomic mechanism of action in A549 cells. Br J Pharmacol 2002;135:511-9.
91. Einstein M, Greenlee M, Rouen G, et al. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. J Steroid Biochem Mol Biol 2004;92:345-56.
92. Kemp JE. Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma. Clin Ther 2003;25: Suppl C:C15-C27.